275 related articles for article (PubMed ID: 12727536)
1. Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.
Ayres A; Bartholomeusz A; Lau G; Lam KC; Lee JY; Locarnini S
J Clin Virol; 2003 May; 27(1):111-6. PubMed ID: 12727536
[TBL] [Abstract][Full Text] [Related]
2. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.
Papatheodoridis GV; Dimou E; Papadimitropoulos V
Am J Gastroenterol; 2002 Jul; 97(7):1618-28. PubMed ID: 12135009
[TBL] [Abstract][Full Text] [Related]
3. Current pharmacotherapy for the treatment of chronic hepatitis B.
Lagget M; Rizzetto M
Expert Opin Pharmacother; 2003 Oct; 4(10):1821-7. PubMed ID: 14521491
[TBL] [Abstract][Full Text] [Related]
4. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
León P; Pozo F; Echevarría JM
Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):133-7. PubMed ID: 14987532
[TBL] [Abstract][Full Text] [Related]
5. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
[TBL] [Abstract][Full Text] [Related]
6. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.
Tacke F; Gehrke C; Luedde T; Heim A; Manns MP; Trautwein C
J Virol; 2004 Aug; 78(16):8524-35. PubMed ID: 15280461
[TBL] [Abstract][Full Text] [Related]
7. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
Delaney WE; Yang H; Westland CE; Das K; Arnold E; Gibbs CS; Miller MD; Xiong S
J Virol; 2003 Nov; 77(21):11833-41. PubMed ID: 14557667
[TBL] [Abstract][Full Text] [Related]
8. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.
Mutimer D; Pillay D; Cook P; Ratcliffe D; O'Donnell K; Dowling D; Shaw J; Elias E; Cane PA
J Infect Dis; 2000 Feb; 181(2):713-6. PubMed ID: 10669360
[TBL] [Abstract][Full Text] [Related]
9. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.
de Man RA; Bartholomeusz AI; Niesters HG; Zondervan PE; Locarnini SA
J Hepatol; 1998 Oct; 29(4):669-75. PubMed ID: 9824278
[TBL] [Abstract][Full Text] [Related]
10. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Zhu Y; Curtis M; Borroto-Esoda K
Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
[TBL] [Abstract][Full Text] [Related]
11. HBV mutations associated with lamivudine therapy.
Lapiński TW; Parfieniuk-Kowerda A; Trzos A; Jaroszewicz J; Kowalczuk O; Nikliński J; Flisiak R
Przegl Epidemiol; 2013; 67(4):611-6, 705-8. PubMed ID: 24741905
[TBL] [Abstract][Full Text] [Related]
12. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
13. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir.
Wolters LM; Hansen BE; Niesters HG; de Man RA
Eur J Gastroenterol Hepatol; 2002 Sep; 14(9):1007-11. PubMed ID: 12352221
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.
Zhang Y; He S; Li QL; Guo JJ
Virus Res; 2013 Nov; 177(2):156-62. PubMed ID: 23968804
[TBL] [Abstract][Full Text] [Related]
15. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
Nafa S; Ahmed S; Tavan D; Pichoud C; Berby F; Stuyver L; Johnson M; Merle P; Abidi H; Trépo C; Zoulim F
Hepatology; 2000 Nov; 32(5):1078-88. PubMed ID: 11050059
[TBL] [Abstract][Full Text] [Related]
16. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
17. Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfected with human immunodeficiency virus-1.
Matthews GV; Pillay D; Cane P; Ratcliffe D; Gazzard B; Nelson M
Clin Infect Dis; 2001 Dec; 33(12):2049-54. PubMed ID: 11698987
[TBL] [Abstract][Full Text] [Related]
18. Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation.
Seehofer D; Rayes N; Neuhaus R; Berg T; Müller AR; Bechstein WO; Neuhaus P
Transpl Int; 2000; 13 Suppl 1():S359-62. PubMed ID: 11112032
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy.
Lai CL; Yuen MF; Hui CK; Garrido-Lestache S; Cheng CT; Lai YP
J Med Virol; 2002 Jul; 67(3):334-8. PubMed ID: 12116023
[TBL] [Abstract][Full Text] [Related]
20. Nucleoside analogues for chronic hepatitis B.
Wolters LM; Niesters HG; de Man RA
Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1499-506. PubMed ID: 11742201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]